5-Amino-1MQ vs AOD-9604: What's the Difference?

5-Amino-1MQ and AOD-9604 are different classes of compound that get grouped together because both are researched for fat loss. 5-Amino-1MQ is a small-molecule NNMT inhibitor that acts inside fat cells, while AOD-9604 is a synthetic fragment of human growth hormone that triggers lipolysis from the outside. Neither is FDA-approved for human use, and only AOD-9604 has been tested in people — where it failed to beat placebo for weight loss.

What Is 5-Amino-1MQ?

5-Amino-1MQ is a synthetic small molecule built on a quinolinium scaffold. Its entire research reputation comes from one target: nicotinamide N-methyltransferase, or NNMT.

NNMT is an enzyme that is overexpressed in adipose tissue and in several metabolic conditions. It consumes methyl groups and influences NAD+ availability inside cells, which affects how fat cells store and burn energy. Blocking NNMT with 5-amino-1MQ reduced adipocyte size and total body fat in diet-induced obese mice, without reducing food intake.

• Compound class: small molecule, not a peptide
• Primary target: NNMT (nicotinamide N-methyltransferase)
• Research route: oral administration in animal studies
• Published human trials: none

Because it appears orally active in rodents, 5-amino-1MQ is often framed as an oral alternative to injectable fat-loss peptides. That framing oversells how much human data actually exists.

What Is AOD-9604?

AOD-9604 is a 16-amino-acid peptide based on the C-terminal region of human growth hormone, residues 176–191. It was engineered to keep the fat-metabolizing piece of hGH while removing the parts tied to growth and glucose effects.

Laboratory work showed that AOD-9604 can stimulate lipolysis and inhibit lipogenesis in fat cells. Early studies also suggested it did not raise IGF-1 or blood glucose the way full growth hormone does, which made it look like a clean, targeted fat-loss agent.

Human data told a different story. A Phase IIb trial of oral AOD-9604 did not produce weight loss meaningfully better than placebo, and commercial development was discontinued.

5-Amino-1MQ vs AOD-9604: Side-by-Side Comparison

Feature	5-Amino-1MQ	AOD-9604
Compound type	Small molecule	Synthetic peptide (hGH fragment 176–191)
Main mechanism	NNMT inhibition; shifts fat-cell energy metabolism	Stimulates lipolysis; inhibits lipogenesis
Common research route	Oral	Subcutaneous injection; oral in trials
Effect on IGF-1	Not a growth-hormone-axis compound	Minimal in published trials
Human trial results	No human trials published	Phase IIb failed to beat placebo for weight loss
FDA status	Not approved for human use	Not approved for human use
Regulatory notes	Sold as a research chemical only	Banned by WADA; not a legal dietary supplement ingredient

How These Compounds Are Studied

Published protocols are not dosing recommendations. Both compounds are sold for laboratory research only and are not intended for human consumption.

Compound	Research route	Frequency studied	Duration studied	Human evidence
5-Amino-1MQ	Oral	Daily	Weeks in rodent models	None published
AOD-9604	Subcutaneous; oral	Daily	12-week human trial program	Phase IIb, no significant weight loss vs. placebo

5-Amino-1MQ has no published human safety data, so its risk profile in people is unknown. Anyone weighing a research chemical against a prescribed treatment should speak with a healthcare professional first.

Why the Mechanisms Matter More Than the Label

Both compounds get marketed with the words "fat loss," but they act on unrelated biology. 5-Amino-1MQ changes methylation and NAD+ metabolism inside adipocytes. AOD-9604 behaves like a hormone fragment signaling fat cells from the outside.

That gap shapes everything downstream: route of administration, half-life, side-effect profile, and how a study would be designed around each molecule. Stacking or directly comparing them rarely makes biological sense, because they do not share a pathway.

Safety, Legality, and the Bottom Line

• 5-Amino-1MQ has no published human safety data, so nobody knows its real risk profile in people.
• AOD-9604 failed its most important human weight-loss trial and is not approved for any medical use.
• AOD-9604 is prohibited by the World Anti-Doping Agency, even though it failed as a drug.
• Neither compound can legally be sold as a dietary supplement ingredient in the United States.
• Neither compound replaces clinically proven weight-management care, and a licensed healthcare professional should be part of any decision.

Related Comparisons Researchers Search For

If the question is visceral fat in humans, aod 9604 vs tesamorelin is the sharper comparison, because tesamorelin carries FDA approval for HIV-associated lipodystrophy while AOD-9604 carries none.

When appetite and incretin signaling are the variables of interest, aod 9604 vs retatrutide is more relevant, since retatrutide is a triple agonist backed by large clinical trials.

Researchers focused on insulin sensitivity rather than the growth hormone axis often turn to aod 9604 vs mots-c, and stacking questions usually lead to aod-9604 vs cjc-1295 ipamorelin, which pairs a GH fragment with GHRH- and ghrelin-pathway peptides.

One naming trap is worth flagging: aod 9604 vs frag 176 191 usually describes the same molecule, so any difference between listings comes down to vendor purity and labeling rather than chemistry.

The Bottom Line on 5-Amino-1MQ vs AOD-9604

For human outcomes, AOD-9604 has the more informative track record — and it is a negative one. For mechanism research, 5-Amino-1MQ is the more novel compound, with a defined target and reproducible rodent findings.

Neither belongs in a personal weight-loss plan. Both are research chemicals without approval for human use, and any weight-management decision should go through a licensed healthcare professional.

COMMON QUESTIONS

Frequently Asked Questions

Is 5-amino-1MQ a peptide like AOD-9604?

No. 5-Amino-1MQ is a small molecule, while AOD-9604 is a synthetic peptide fragment of human growth hormone. That difference means different administration routes, half-lives, and mechanisms of action.

Did AOD-9604 actually work for weight loss in humans?

A Phase IIb human trial of oral AOD-9604 did not produce weight loss significantly better than placebo, which is why development stopped. Earlier laboratory studies showed fat-burning effects in cells, but those results did not carry over into larger human testing. AOD-9604 is not FDA-approved for any medical use.

Is it legal to buy 5-amino-1MQ or AOD-9604 in the US?

Neither compound is FDA-approved for human use, and neither can legally be sold as a dietary supplement ingredient in the United States. They are sold as research chemicals labeled "not for human consumption," and AOD-9604 is banned by WADA for athletes. Talk to a healthcare professional before considering any unapproved compound.